安罗替尼治疗晚期非小细胞肺癌的疗效研究  

Efficacy of anlotinib in the treatment of advanced non-small cell lung cancer

作　　者：魏祯瑶 皇甫娟[1] 张慧辉[1] WEI Zhenyao;HUANGFU Juan;ZHANG Huihui(Jiaozuo People's Hospital,Jiaozuo 454002,China)

机构地区：[1]焦作市人民医院,河南焦作454002

出　　处：《临床医药实践》2023年第12期883-887,共5页Proceeding of Clinical Medicine

基　　金：2020年度河南省医学科技攻关计划联合共建立项项目(项目编号:LHGJ20200835)。

摘　　要：目的:探讨安罗替尼联合培美曲塞+卡铂方案治疗表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)获得性耐药晚期非小细胞肺癌(NSCLC)的治疗效果。方法:选取2019年12月—2022年12月收治的74例EGFR-TKI获得性耐药晚期NSCLC患者为研究对象,将选择安罗替尼+培美曲塞+卡铂治疗方案的37例患者归为联合组,选择培美曲塞+卡铂治疗方案的37例患者归为对照组。比较治疗前及治疗5个周期后两组患者疾病控制率、无进展率、总生存率及治疗3个周期后患者细胞角蛋白19可溶性片段(CYFRA21-1)、鳞状上皮细胞抗原(SCC)等血清相关标志物水平和不良反应情况。结果:治疗前两组患者SCC,CYFRA21-1比较差异无统计学意义(P>0.05)。治疗后两组患者SCC,CYFRA21-1较治疗前显著降低(P<0.05);联合组患者SCC,CYFRA21-1明显低于对照组(P<0.05),疾病控制率明显高于对照组(P<0.05)。两组患者无进展生存率、总生存率、化疗CTCAE评定结果比较差异无统计学意义(P>0.05)。结论:安罗替尼联合培美曲塞+卡铂方案治疗EGFR-TKI获得性耐药晚期NSCLC患者可发挥显著抗肿瘤作用,安全性较高。Objective:To explore the therapeutic effect of anlotinib combined with pemetrexed+carboplatin regimen in the treatment of advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)acquired resistance.Methods:All 74 patients with advanced NSCLC with EGFR-TKI acquired resistance admitted to the hospital from December 2019 to December 2022 were selected as research subjects for retrospective study.37 patients who chose the treatment regimen of anlotinib+pemetrexed+carboplatin were classified into combined group,and 37 patients who chose the treatment regimen of pemetrexed+carboplatin were regarded as control group.The effective rate ORR,disease control rate,progression-free survival rate and overall survival rate before treatment and after 5 cycles of treatment,levels of serum related markers such as cytokeratin 19 soluble fragment(CYFRA21-1)and squamous cell carcinoma antigen(SCC)after 3 cycles of treatment were compared between the two groups of patients.Results:Before treatment,the levels of SCC and CYFRA21-1 in both groups were similar(P>0.05).After treatment,the levels of SCC and CYFRA21-1 in the two groups were significantly decreased compared with those before treatment(P<0.05),and the levels in combined group were significantly lower than those in control group(P<0.05).The disease control rate was significantly higher than that in control group(P<0.05).The progression-free survival rate,overall survival rate and CTCAE evaluation results of chemotherapy were similar in the two groups(P>0.05).Conclusion:The combination of anlotinib and pemetrexed+carboplatin regimen in treating advanced NSCLC patients with EGFR-TKI acquired resistance can play a significant anti-tumor effect,and the drug regimen has high safety,so it is recommended to be widely used in clinical practice.

关 键 词：安罗替尼 酪氨酸激酶抑制剂 获得性耐药 非小细胞癌症 

分 类 号：R734.2[医药卫生—肿瘤]